

## CURRICULUM VITAE

### Catherine (Cathy) M. Tangen

Current address: SWOG Statistical Center  
Public Health Division  
Fred Hutchinson Cancer Research Center  
1100 Fairview Avenue N, M3-C102  
Seattle, WA 98109-1024

Phone number: W: (206) 667-2933

Email address: [ctangen@fhcrc.org](mailto:ctangen@fhcrc.org)

Education: University of Washington, B.S. (Zoology) 1985  
University of North Carolina, M.S.  
(Biostatistics) 1990  
University of North Carolina, Dr.PH  
(Biostatistics) 1997

#### **POSITIONS:**

Assistant Member, Fred Hutchinson Cancer Research Center (SWOG), Seattle, WA, 1999-2004  
Associate Member, Fred Hutchinson Cancer Research Center (SWOG), Seattle, WA 2004-2008  
Full Member, Fred Hutchinson Cancer Research Center (SWOG), Seattle, WA 2008-present  
Affiliate Professor, Department of Biostatistics, U. of Washington, Seattle, WA 2009-2105

#### **SWOG**

Deputy Director, SWOG Statistical Center 2013 -  
SWOG Board of Governors 2013 -  
SWOG Executive Committee 2013 –  
Member of SWOG Conflict Management Committee, 2006 -  
Member of SWOG Data and Safety Monitoring Committee, 2005 -  
Genitourinary Committee Statistician 1999 –  
PI, PCPT and SELECT UM1 2013-

#### **Current Professional Activities:**

##### DSMC for NIH sponsored trials

Member of Prostate Active Surveillance Study (PASS) DSMC (UW/Hutch), 2008 -  
Member of Robotic Cystectomy DSMC 2011-present

#### **Hutch**

Co-chair Clinical Trials Affinity Group

#### **NIH**

Member, NCI Genitourinary Cancer Scientific Steering Committee, 2008-  
Member, NCI Prostate Cancer Task Force, 2010-  
Invited faculty, Non-muscle Invasive Bladder Cancer, Clinical Trial Planning Meeting, 2015  
Invited faculty, Cancer Prevention Think Tank, 2015

#### **Journals:**

- Cancer Prevention Research Journal, Editorial Board 2008-present
- JCO, Editorial Board, 2014 - present

**AREAS OF INTEREST:** Analysis of Longitudinal Data, Categorical Data Analysis, Nonparametric Methods, Survival Analysis, Clinical Trials

### **PUBLICATIONS - Refereed Journals**

#### **Submitted or in Press**

- Chan JM, Darke A, Penney KL, Tangen C, Goodman P, Lee G-SM, Sun T, Peisch S, Tinianow A, Rae JR, Klein EA, Thompson IM, Kantoff PW, Mucci LA. Selenium- or vitamin E –related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. Accepted 4/16 CEBP.
- Tangen CM, Goodman PJ, Till C, Schenk J, Lucia MS, Thompson IM. Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors. Results from two large randomized clinical trials. Submitted 4/16.
- Unger JM, Till C, Thompson, Jr. IM, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL. Long-term Consequences of Finasteride versus Placebo in the Prostate Cancer Prevention Trial. Under revision at JNCI.
- Lerner SP, . . . ., Catherine M. Tangen, . . . ., Quale DZ (approx. 40 authors). Summary and recommendations from the NCI's clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. Submitted to Bladder Journal 3/16.
- Chen H, Liu X, Brendler C, Ankerst D, Leach, R Goodman P, Lucia MS, Tangen C, Wang L, Hsu F-C, Sun J, Kader A, Isaacs W, Helf B, Zheng S, Thompson I, Platz E, Xu J. Prostate cancer risk assessment by genetic risk score in men with or without family history. submitted.

#### **Published**

##### **2015-2016**

- 1) Hussain M, Tangen C (co-primary authors), Celestia Higano, Nicholas Vogelzang, and Ian Thompson. Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details JCO Jan 20, 2016:280-285.
- 2) Winchester DA, Gurel B, Till C, Goodman P, Tangen C, Santella R, Paris-Johnson T, Leach R, Thompson IM, Xu J, Zheng S, Lucia MS, Lippmann S, Parnes H, Isaacs W, Drake C, DeMarzo A, Platz E. Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the PCPT. Prostate 76(6):565-574, 2016.
- 3) Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Karim Fizazi, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KM, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. JCO published online on March 7, 2016; DOI:10.1200/JCO.2015.65.7270
- 4) Minasian L, Tangen CM, Wickerham DL. Ongoing use of data and specimens from NCI-sponsored cancer prevention clinical trials in the Community Clinical Oncology program. Seminars in Oncology 42(5):748-763, 2015.
- 5) Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. Int'l J of Cancer 136(8):1856-1862, 2015.
- 6) Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncol. 2015 Dec 23:1-9.
- 7) Cassano PA; Guertin KA; Kristal AR; Ritchie KE; Bertoia ML; Arnold KB; Crowley JJ; Hartline J; Goodman PJ; Tangen CM; Minasian LM; Lippman SM; Klein E. A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. Respiratory Research. 16:35, 2015.

- 8) Winchester D, Till C, Goodman P, Tangen C, Santella R, Leach R, Xu J, Zheng X, Thompson IM, Lucia MS, Lippman SM, Parnes H, Dluzniewski H, Isaacs W, De Marzo A, Drake C, Platz E. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. *Prostate* 75(13):1403-1418, 2015.
- 9) Chau C, Price D, Till C, Goodman P, Chen X, Leach R, Johnson-Pais T, Hsing A, Hoque A, Tangen C, Chu L, Parnes H, Schenk J, Reichardt J, Thompson I, Figg W. Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *PLOS ONE* DOI:10.1371/journal.pone.0126672 May 8, 2015.
- 10) Yu E, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath E, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang N, Quinn D, Cheng H, Plymate SR, Hussain M, Tangen CM, Thompson, IM. A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. *J Clin Oncol* 33(14):1601-1608, 2015.
- 11) Umbehr M, Gurel B, Murtola T, Sutcliffe S, Peskoe S, Tangen C, Goodman P, Thompson IM, Lippman S, Lucia MS, Parnes H, Drake C, Nelson W, DeMarzo A, Platz E. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng/mL, normal DRE, and negative for prostate cancer. *Prostate Cancer and Prostatic Diseases* 18:264-269, 2015.
- 12) Christen W, Glynn R, Gaziano J, Tangen C, Crowley J, Goodman P, Darke A, Lippman SM, Lad T, Bearden J, Goodman G, Minasian L, Thompson I, Blanke C, Klein E. Age-related cataract in a randomized trial of selenium and vitamin E in men: The SELECT Eye Endpoints (SEE) Study. *JAMA Ophthalmology*, 133(1):17-24, 2015.
- 13) Hoque A, Yao S, Till C, Kristal A, Goodman P, Hsing A, Tangen C, Platz E, Stanczyk F, Reichardt J, VanBokhoven A, Neuhauser M, Santella R, Figg W, Price D, Parnes H, Lippman S, Ambrosone C, Thompson I. Effect of finasteride on serum androstenedione and risk of prostate cancer within the Prostate Cancer Prevention Trial: differential effect on high and low grade disease. *Urology* 85(3):616-620, 2015.

#### **2014 or earlier**

- 14) Arnold K, Hermos J, Anderson K, Minasian L, Tangen CM, Probstfield J, Cook E. Retention of black and white participants in the Selenium and Vitamin E Cancer Prevention Trial (S0000). *CEBP* 23(12):2895-2905, 2014.
- 15) Kristal A, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser M, Thompson IM, Meyskens F, Goodman G, Minasian L, Parnes H. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. *CEBP* 23(8):1494-504, 2014.
- 16) Martinez E, Darke A, Tangen C, Goodman P, Fowke J, Klein EA, Abdulkadir A. A functional variant in NKX3.1 associated with prostate cancer risk in the SELECT Trial. *Cancer Prev Research*, 7(9):950-957, 2014.
- 17) Cassano P, Guertin K, Kristal A, Ritchie K, Bertoia M, Arnold K, Crowley J, Hartline J, Goodman P, Tangen C, Minasian L, Lippman S, Klein E. A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. *Respiratory Research* 16:35, 2015.
- 18) Gurel B, Lucia MS, Thompson IM, Goodman P, Tangen C, Kristal A, Parnes H, Lippman S, Sutcliffe S, Peskoe S, Drake C, Nelson W, DeMarzo A, Platz E. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. *CEBP* 23(5):847-56, 2014.
- 19) Gritz E, Arnold K, Moinpour C, Burton-Chase A, Tangen C, Probstfield J, See W, Lieber M, Caggiano V, Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman P, Padberg R, Minasian L, Meyskens F, Thompson IM. Factors associated with adherence to an end-of-study biopsy: lessons from the Prostate Cancer Prevention Trial. *CEBP* 23(8):1638-1648, 2014.
- 20) Schenk J, Till C, Tangen C, Goodman P, Song X, Torkko K, Kristal A, Peters U, Neuhauser M. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. *CEBP* 23(8):1484-1493, 2014.

- 21) Christodouleas, JP, Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Tangen CM, Lerner SP, Guzzo TJ, Malkowicz, SB. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. *Cancer* 120(8):1272-1280, 2014.
- 22) Thompson IM, Tangen CM. Prostate cancer screening comes of age. *The Lancet* 384:2004-2005, 2014.
- 23) Ankerst DP, Till C, Boeck A, Goodman PJ, Tangen CM, Thompson IM. Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores and AUA symptom score. *Urology* 82(5):1076-1081, 2014.
- 24) Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhauser ML, Klein EA, Lucia MS, Thompson IM, Kristal AR. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. *Journal of Urology* 192(2):379-384, 2014.
- 25) Figg WD, Chau CH, Price DK, Till C, Goodman PG, Cho Y, Varella-Garcia M, Reichardt J, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS. Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Urology* 84(1):127-131, 2014.
- 26) Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. *JNCI* 106(9):2014.
- 27) Goldkorn A, Ely B, Quinn DI, Tangen CM, et al. Circulating tumor cell counts are prognostic of overall survival in S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration resistant prostate cancer. *JCO* 32:1136, 1142, 2014.
- 28) Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum biomarkers of bone metabolism in castration resistant prostate cancer patients with skeletal metastases. *JNCI* 106(4):1-9, 2014.
- 29) Kristal AR, Darke AK, Morris S, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. *JNCI* 106(3):1-8, 2014.
- 30) Thompson IM, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of participants in the Prostate Cancer Prevention Trial. *N Eng J Med* 369(7):603-610, 2013.
- 31) Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan compared to docetaxel and placebo for men with advanced castration resistant prostate cancer: S0421. *Lancet Oncology* 14:893-900, 2013.
- 32) Hussain M. Tangen CM. Berry DL. Higano CS. Crawford ED. Liu G. Wilding G. Prescott S, Sundaram SK. Small EJ. Dawson NA. Donnelly BJ. Venner PM. Vaishampayan UN. Schellhammer PF. Quinn DI. Raghavan D. Ely B. Moinpour CM. Vogelzang NJ. Thompson IM Jr. Intermittent versus continuous androgen deprivation in prostate cancer. *N Engl J Med*. 368(14):1314-25, 2013.
- 33) Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal A. Should modest elevations in PSA, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? *Amer J of Epi* 178(5):741-751, 2013.
- 34) Vickers AJ, Sjoberg DD, Ankerst DP, Tangen CM, Goodman PJ, Thompson IM. The prostate cancer prevention trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. *Cancer* 119:3007-3011, 2013.
- 35) Goodman PJ, Hartline JA, Tangen CM, Crowley JJ, Minasian LM, et al. Moving a randomized clinical trial into an observational cohort. *Clin Trials* 10(1):131-142, 2013.
- 36) Ankerst D, Till C, Boeck A, Goodman P, Tangen C, Thompson I. The impact of prostate volume, number of biopsy cores, and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. *Journal of Urology* 190(1):70-76, 2013.

- 37) Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes LH, Klein EA, Kristal AR. Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. *JNCI* 105:1132-1141, 2013.
- 38) Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM, Thompson IM. S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin. *J Urol* 190(4):1200-1204, 2013.
- 39) Neuhouser ML, Platz E, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor binding proteins and prostate cancer risk: Results from the PCPT. *Cancer Prev Res* 6(2):91—99, 2013.
- 40) Thompson IM, Tangen C. Prostate Cancer: uncertainty and a way forward. *NEJM* 367:270-1, 2012.
- 41) Tangen CM, Hussain MHA, Higano CS, Eisenberger MA, Small EJ, Wilding G, et al. Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8894 & S9346). *J Urology* 188:1164-1169, 2012.
- 42) LeBlanc M, Tangen C. Choosing Phase II Endpoints and Designs: Evaluating the Possibilities. *Clin Cancer Res* 18:2130-2132, 2012.
- 43) Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas G, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-Year follow-up of neoadjuvant therapy with goserelin acetate and flutamide prior to radical prostatectomy for clinical T3 and T4 prostate cancer: Update on SWOG study S9109. *Urology*. 79(3):633-7, 2012 Mar.
- 44) Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR. Indications for and use of non-steroidal anti-inflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial. *Amer J of Epi* 176(2):156-163, 2012.
- 45) Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser MI, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, VanBokhoven A, Lippman SM, Hsing AW. Associations of serum sex steroid hormone and 5 $\alpha$ -androstane-3 $\alpha$ , 17 $\beta$ -diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. *CEBP* 21(10):1823-1832, 2012.
- 46) Marshall J, Tangen C, Sakr W, Wood D, Berry D, Klein E, Lippman S, Parnes H, Alberts D, Jarrard D, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. *Cancer Prev Res* 4(11):1761-1769, 2011.
- 47) Vickers A, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate specific antigen velocity in prostate cancer detection. *JNCI* 103(6):462-469, 2011.
- 48) Dorff, TB, Flaig TW, Tangen CM, Hussain M, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson I, Glode LM. Adjuvant Androgen Deprivation for High Risk Prostate Cancer after Radical Prostatectomy: Southwest Oncology Group (SWOG) Study S9921. replied to reviewers and resubmitted to *J Clin Oncol* 29:2040-2045, 2011.
- 49) Smith DC, Tangen CM, Van Veldhuizen PJ, Harrer GW, Golshayan A, Mills GM, Vogelzang NJ, Thompson IM, Hussain MHA. Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate: Southwest Oncology Group (SWOG) S0032. *Urology* 77(5):1172-1176, 2011.
- 50) Schenk J, Arnold K, Tangen C, Neuhouser M, Lin D, White E, Thompson I, Kristal A. No Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer When Detection Bias is Minimized: Results From the Prostate Cancer Prevention Trial. *Am J Epidemiol* 173(12):1419-1428, 2011.
- 51) Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, et al. Serum estrogen levels and prostate cancer risk in the Prostate Cancer Prevention Trial: a nested case-control study. *Cancer Causes and Control* 22:1121-1131, 2011.

- 52) Tang L, Yao S, Till C, Goodman PJ, Tangen CM, UuY, Kristal AR, Platz EA, Neuhauser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Hoque A, Lippman SM, Thompson IM, Ambrosone CB. Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Carcinogenesis* 32(10):1500-1506, 2011.
- 53) Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer. *JAMA* 306(14):1549-1556, 2011.
- 54) Lotan Y, Goodman PJ, Youssef RF, Svatek RS, Shariat SF, Tangen CM, Thompson IM, Klein EA. Evaluation of Vitamin E and selenium supplementation on the prevention of bladder cancer in SWOG-coordinated SELECT. Accepted by *J Urology* 11/2011.
- 55) Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, deVere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of S8710. *BJU Int* 108(5):693-699, 2011.
- 56) Solit DB, Tangen C, Lara PN, Jr. Developing and implementing more informative phase II oncology trials. *ASCO Educational Book*, 2011.
- 57) Moodie PF, Saville BR, Koch GG, Tangen CM. Estimating covariate-adjusted log hazard ratios for multiple time intervals in clinical trials using nonparametric randomization based ANCOVA. *Statistics in Biopharmaceutical Research* 3(2):232-241, 2011
- 58) Petrylak DP, Tangen CM, Van Veldhuizen PJ, Jr, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. *BJU Int* 105(3):317-21, 2010. PMID: 19888985
- 59) Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen C, Kristal A, Lucia S, Wang Q, Kappil M, Thompson I, Hsing AW, Parnes H, Santella RM. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. *Cancer Prev Res* 3(4):478-483, 2010. PMID: 20332306; PMCID: PMC2853720
- 60) Schenk JM, Kristal AR, Neuhauser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. *Am J Epidemiol* 171(5):571-582, 2010. PMID: 20142396, PMCID: PMC2842217
- 61) Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JKV, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD. Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the Prostate Cancer Prevention Trial. *J Urol* 184:2297-2302, 2010.
- 62) Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen C, Kristal A, Lucia S, Wang Q, Kappil M, Thompson I, Hsing AW, Parnes, H, Santella RM. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. *Cancer Prev Res* 3(4):478-483, 2010.
- 63) Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhauser ML, Parnes HL, Reichardt JKV, Santella RM, Till C, Lippman SM. Transition of a clinical trial into translational research: the prostate Cancer Prevention Trial experience. *Cancer Prev Res* 3(12):1523-1533, 2010. PMID: 21149329
- 64) deVere White RW, Lara PN, Jr, Goldman B, Tangen CM, Smith DC, Wood DP, Jr, Hussain MHA, Crawford ED. A sequential treatment approach to myoinvasive urothelial cancer: a Phase II Southwest Oncology Group trial (S0219). *J Urol* 181:2476-2481, 2009. PMID: 19371909. PMCID: PMC2769926
- 65) Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group trials 9346 (Intergroup study 0162) and 9916. *J Clin Oncol* 27(15):2450-2456, 2009. PMID: 19380444. PMCID: PMC2684851

- 66) Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. *Urol Oncol* 27(2):155-159, 2009. PMID: 18367117. PMCID: PMC2695968
- 67) Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Higano E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol* 181(3):956-962, 2009. PMID: 19167731
- 68) Lara PN, Jr, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group trial S8949. *J Urol* 181(2):512-517, 2009. PMID: 19100570. NIHMS244861
- 69) Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer. *J Urol* 182(2):499-508, 2009. PMID: 19524966
- 70) Dorff TB, Tangen CM, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MHA. Cooperative group trials--Southwest Oncology Group (SWOG) innovations in advanced prostate cancer. *Ther Adv Med Oncol* 1(2):69-77, 2009. PMID: None
- 71) Crawford ED, Tangen CM. Clinical integration: laudable, but challenging. *Nat Rev Urol* 6(6):297-298, 2009. PMID: 19498403
- 72) Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Cancer* 115(6):3661-3669, 2009. PMID: 19598210. PMCID: PMC2739798
- 73) Schenk JM, Kristal AR, Neuhaus ML, Tangen CM, White E, Lin DW, Thompson IM. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. *The Prostate* 69(12):1303-1311, 2009. PMID: 19475640. PMCID: PMC2838168
- 74) Flaig TW, Tangen CM, Hussain MHA, Stadler WM, Raghavan D, Crawford ED, Glodé LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. *J Clin Oncol* 26(9):1532-1536, 2008. PMID: 18349405
- 75) Thompson IM, Tangen CM, Kristal AR. Prostate-specific antigen: A misused and maligned prostate cancer biomarker. *JNCI* 100(21):1487-1488, 2008.
- 76) Thompson IM, Tangen CM, Lucia MS. The Prostate Cancer Prevention Trial and the future of chemoprevention. *BJU Int* 101:933-934, 2008. PMID: 18353157
- 77) Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman P, Parnes H, Coltman C A J. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. *J Urol* 180:544-547, 2008. PMID: 18550097
- 78) Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford ED. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin. *Cancer* 112(10):2181-2187, 2008. PMID: 18404692
- 79) Sartor AO, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED. Antiandrogen withdrawal in castrate-refractory prostate cancer. *Cancer* 112(11):2393-2400, 2008. PMID: 18383517
- 80) Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman CA, Jr. Does the level of prostate cancer risk affect cancer prevention with finasteride? *Urology* 71(5):854-857, 2008. PMID: 18455628. PMID: PMC2692669
- 81) Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. *Cancer Prev Res* 1(3):174-181, 2008. PMID not available at this time
- 82) Song Y, Tangen C, Goodman P, L PH, Lucia MS, Thompson IM, Kristal AR. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. *The Prostate* 68:281-286, 2008. PMID: 18163420

- 83) Neuhaus ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the Prostate Cancer Prevention Trial. *The Prostate* 68:1477-1486, 2008. PMID: 18618736. PMCID: PMC2564287
- 84) Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. *J Urol* 180:1303-1308, 2008. PMID: 18707724
- 85) Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Higano E, Forman JD, Thompson IM, Crawford ED. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. *J Urol* 180:2453-2458, 2008. PMID: 18930488
- 86) Thompson IM, Jr, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA, Jr. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. *J Urol* 177:1749-1752, 2007.
- 87) Thompson IM, Lucia MS, Tangen CM. Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present. *Int J Epidemiol* 36(2):287-289, 2007.
- 88) Wolman SR, Goldman B, Slovak ML, Tangen C, Persons DL, Wood D. Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. *Cancer Genet Cytogenet* 176:22-27, 2007.
- 89) Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Higano E, Forman JD, Thompson IM, Crawford ED. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. *J Clin Oncol* 25(16):2225-2229, 2007.
- 90) Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T<sub>a</sub> bladder cancer. *J Urol* 177:1727-1731, 2007.
- 91) Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Higano ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM. Guideline for the management of clinically localized prostate cancer: 2007 update. *J Urol* 177:2106-2131, 2007.
- 92) Cookson MS, Aus G, Burnett AL, Canby-Higano ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. *J Urol* 177:540-545, 2007.
- 93) Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA, Jr. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. *J Clin Oncol* 25(21):3076-3081, 2007.
- 94) Ryan CW, Goldman BH, Lara PN, Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan C-X, Drabkin HA, Crawford ED. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. *J Clin Oncol* 25(22):3296-3301, 2007. PMID: 17664477
- 95) Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* 99(18):1375-1383, 2007. PMID: 17848673
- 96) Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. *J Urol* 178:1946-1951, 2007. PMID: 17868721
- 97) Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group study. *Clin Cancer Res* 12(7):2178-2184, 2006.



- 98) Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, Crawford ED. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer. *Cancer* 107(3):489-496, 2006.
- 99) Thompson IM, Chi C, Ankerst D Pauler, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. *J Natl Cancer Inst* 98(16):1128-1133, 2006.
- 100) Thompson IM, Ankerst D Pauler, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* 98(8):529-534, 2006.
- 101) Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. *Cancer* 106(2):320-328, 2006.
- 102) Goodman PJ, Thompson IM, Jr, Tangen CM, Crowley JJ, Ford LG, Coltman CA, Jr. The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. *Urology* 175:2234-2242, 2006.
- 103) Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED. Southwest Oncology Group phase I study of arsenic trioxide in patients with refractory germ cell malignancies. *Cancer* 106(12):2624-2629, 2006.
- 104) Petrylak DP, Ankerst D Pauler, Jiang CS, Tangen CM, Hussain MHA, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. *J Natl Cancer Inst* 98(8):516-521, 2006.
- 105) Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). *J Clin Oncol* 24(24):3984-3990, 2006.
- 106) SCT Working Group on Data Monitoring, Dixon DO, Freedman RS, Herson J, Hughes M, Kim K, Silverman MH, Tangen CM. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. *Clin Trials* 3:313-319, 2006.
- 107) Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: result of a randomized prospective clinical trial. *JAMA* 296:2329-2335, 2006.
- 108) Thompson IM, Tangen CM, Does prostate volume affect accurate grading of prostate biopsies? *Nat Clin Pract Uro* 3(6):298-299, 2006.
- 109) Grossman HB, Tangen CM, Cardon-Cardo C, Cote R, Waldman FM, deVere White, RW, Karnad AB, Glode M, Crawford ED. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy. *Oncol Rep* 16(4):807-810, 2006.
- 110) Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. *Cancer Epidemiol Biomarkers Prev* 15(8):1479-1484, 2006.
- 111) Klein EA, Tangen CM, Goodman PJ, Lippman SM, Thompson IM. Assessing benefit and risk in the prevention of prostate cancer: the Prostate Cancer Prevention Trial revisited. *J Clin Oncol* 23(30):7460-7466, 2005.
- 112) Thompson IM, Tangen CM, Klein EA, Lippman SM. Phase III prostate cancer prevention trials: are the costs justified? *J Clin Oncol* 23(32):8161-8164, 2005.
- 113) Sarosdy MF, Tangen CM, Weiss GR, Nestok BR, Benson MC, Schellhammer PF, Sagalowsky AI, Wood DP Jr, Crawford ED. A phase II clinical trial of oral bropiramine in combination with

- intravesical bacillus Camette-Guérin for carcinoma in situ of the bladder: A Southwest Oncology Group study. *Urol Oncol* 23(6):386-389, 2005.
- 114) Hussain M, Tangen CM, Lara PN, Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group Trial S0111. *J Clin Oncol* 23(24):8724-8729, 2005.
- 115) Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. *JAMA* 294(23):2996-3002, 2005.
- 116) Tangen CM, Goodman PJ, Crowley JJ, Thompson IM. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. *J Urol* 171:S64-S67, 2004.
- 117) Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman CA Jr, Ford LG, Thompson IM. Implementation of the Prostate Cancer Prevention Trial (PCPT). *Control Clin Trials* 25:203-222, 2004.
- 118) Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level  $\leq 4.0$  ng per milliliter. *N Engl J Med* 350(22):2239-2246, 2004.
- 119) Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, ED Crawford. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J Urol* 171:1071-1076, 2004.
- 120) Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 351(15):1513-1520, 2004.
- 121) Beer TM, Tangen CM, Bland LB, Thompson IM, Crawford ED. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. *J Urol* 172:2213-2217, 2004.
- 122) Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. *Urology* 64(6):1182-1186, 2004.
- 123) Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. *J Urol* 169(1):164-169, 2003.
- 124) Thompson IM, Tangen C, Goodman P. The prostate cancer prevention trial: design, status, and promise. *World J Urol* 21:28-30, 2003.
- 125) Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 349(3):215-224, 2003.
- 126) Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, devere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 349(9):859-866, 2003.
- 127) Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Ten-year survival in patients with metastatic prostate cancer. *Clin Prostate Cancer* 2(1):41-45, 2003.
- 128) Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J, Newman A, Hirsch C, and Tracy RP. Inflammation and coagulation factors in persons  $>65$  years of age with symptoms of depression but without evidence of myocardial ischemia. *American Journal of Cardiology* 89(4):419-424, 2002.
- 129) Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. *J Urol* 168:1008-1012, 2002.

- 130) Klein CE, Tangen CM, Braun TJ, Hussain MHA, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR, Crawford ED. SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group Study. *Prostate* 52:264-268, 2002.
- 131) Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. *Cancer Res* 62:5218-5222, 2002.
- 132) Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, deVere White R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, phase II Southwest Oncology Group Study 9109. *J Urol* 168:2016-2019, 2002.
- 133) Fried L, Tangen C, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: Evidence for a phenotype. *Journal of Gerontology* 56A(3):M146-M156, 2001.
- 134) Tangen CM, Koch GG. Nonparametric analysis of covariance for confirmatory randomized clinical trials to evaluate dose-response relationships. *Statistics in Medicine* 20:2585-2607, 2001.
- 135) Thompson IM, Tangen CM, Tolcher A, Crawford ED, Eisenberger M, Moinpour CM. Re: Association of African-American ethnic background with survival in men with metastatic prostate cancer - Response. *JNCI* 93(15):1174-1175, 2001
- 136) Tangen CM, Koch GG. Nonparametric covariance methods for incidence density analysis of time-to-event data from a randomized clinical trial. *Statistics in Medicine* 19:1039-1058, 2000.
- 137) Yaffe K, Haan M, Byers A, Tangen C, and Kuller L. Estrogen use, APOE, and cognitive decline. *Neurology* 54:1949-1953, 2000.
- 138) Aariyo A, Haan M, Tangen C, Rutledge JC, Cushman M, Dobs A, Furberg CD. Depressive symptoms and risk of coronary heart disease and mortality in elderly Americans. *Circulation* 102(15):1773-1779, 2000.
- 139) Tangen CM, Koch GG. Complementary nonparametric analysis of covariance for logistic regression in a randomized clinical trial. *J Biopharm Stat* 9(1):45-66, 1999.
- 140) Tangen CM, Koch GG. Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival rate estimation in a randomized clinical trial. *J Biopharm Stat*, 9(2): 307-338, 1999.
- 141) Sloane PD, Davidson S, Knight N, Tangen C, Mitchell CM. Severe Disruptive Vocalizers, *J. American Geriatrics Society*, 47(4):439-445, 1999.
- 142) Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A, Savage PJ. Increased blood glucose and insulin, body size, and incident colorectal cancer. *J Natl Cancer Inst* 91(13):1147-1154, 1999
- 143) Koch GG, Tangen CM. Nonparametric analysis of covariance and its role in non-inferiority clinical trials. *Drug Information Journal* 33(4):1145-1159, 1999.
- 144) Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. *Seminars in Oncology* 26(5):55-60, 1999.
- 145) Koch, GG, Tangen CM, Jung JW, Amara IA. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and nonparametric strategies for addressing them. *Stat Med* 17:1863-1892, 1998.
- 146) Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Haller DG, Laurie JA. Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection. *Ann Intern Med* 129:27-35, 1998.
- 147) Myeloma Trialists' Collaboration Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. *J Clin Oncol* 16(12):3832-3842, 1998.
- 148) Williamson SK, Tangen CM, Maddox AM, Spiridonidis CH, Macdonald JS. Phase II evaluation of low dose continuous 5-fluorouracil (5FU) and weekly cis-platinum (CDDP) in advanced adenocarcinoma of the stomach: A Southwest Oncology Group study. *Am J Clin Oncol* 18:484-487, 1995.

- 149) Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy for resected stage III colon carcinoma: A final report. *Ann Intern Med* 122:321-326, 1995.
- 150) Fabian C, Giri S, Estes N, Tangen CM, Poplin E, et al. Adjuvant continuous infusion 5FU, whole abdominal radiation and tumor bed boost in Dukes C2 colon carcinoma: A Southwest Oncology Group study. *International Journal of Radiation Oncology, Biology, Physics* 32:457-464, 1995.
- 151) Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. *J Clin Oncol* 13:2936-2943, 1995.
- 152) Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, Eyre HJ, Canefield V, Cruz AB, Gagliano R, Tangen CM, Rivkin S. Adjuvant chemotherapy with 5-FU, Adriamycin and Mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. *Ann Surg Oncol* 2:488-494, 1995.
- 153) Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Bickers JN, Weiss GR, Neidhard JA, Macdonald J. Phase II study of 5-FU and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. *J Clin Oncol* 13:1303-1311, 1995.
- 154) Berenberg J, Tangen C, Macdonald JS, Hutchins LF, Natale RB, Oishi N, Guy JT, Fleming T. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group study. *Cancer* 76:715-719, 1995.
- 155) Poplin EA, Tangen CM, Harvey WH, Macdonald JS. Hepatoma/merbarone. *Invest New Drug* 12:337-340, 1994.
- 156) Marshall ME, Tangen CM, Berenberg JL, Balcerzak SP, Brown T, Macdonald JS. Treatment of advanced colorectal carcinoma with 5-fluorouracil, leucovorin and Roferon-A(r): A Southwest Oncology Group study. *Cancer Biotherapy* 9:301-306, 1994.
- 157) Hantel A, Tangen CM, Macdonald JS, Richman SP, Pugh, RP, Pollock, T. Phase II trial of trimetrexate in untreated advanced gastric carcinoma. *Invest New Drugs* 12:155-157, 1994
- 158) Hantel A, Tangen C, Gluck WL, Macdonald JS. Phase II trial of piroxantrone in gastric carcinoma: A Southwest Oncology Group study. *Invest New Drugs* 12:159-161, 1994.
- 159) Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS. Phase II trial of dimethyltriazenoimidazaole carboxamide in patients with metastatic carcinoid: A Southwest Oncology Group study. *Cancer* 73:1505-1508, 1994.
- 160) Jenkins TR, Tangen C, Macdonald JS, Weiss, Chapman R, Hantel A. A phase II trial of piroxantrone in adenocarcinoma of the pancreas: A Southwest Oncology Group study. *Invest New Drugs* 11:329-331, 1993.
- 161) Berenberg JL, Tangen C, Macdonald JS, Barlogie B, Laufman LR. VM26 in gastric cancer: A Southwest Oncology Group study. *Invest New Drugs* 11:333-334, 1993
- 162) Leichman CG, Tangen CM, Macdonald JS, Leimert T, Fleming TR. Phase II trial of amonafide in advanced pancreas cancer: A Southwest Oncology Group study. *Invest New Drugs* 11:219-221, 1993
- 163) Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. *JAMA* 270:943-947, 1993.
- 164) Bukowski RM, Tangen CM, Lee R, Macdonald JS, et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest Oncology Group Study. *J Clin Oncol* 10:1914-1918, 1992.
- 165) Sloane PD, Matthew LJ, Scarborough M, Desai JR, Koch GG, Tangen CM. Physical and pharmacological restraint of nursing home patients with dementia - impact of specialized units. *JAMA* 13:1278-1282, 1991.
- 166) Koch, GG, Tangen CM, Tudor GM, Stokes ME. Comment on a critical look at accumulation analysis and related methods. *Technometrics* 32:137-149, 1990.